Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Intensity Therapeutics, Inc./ 10-Q

Quarterly Report · 10-Q

Intensity Therapeutics, Inc.

INTSNASDAQEQUITYCurrent

Quarterly Report

Filed May 7, 2026Accepted May 7, 2026, 4:01 PM EDTCIK 1567264Accession 0001567264-26-000046
View company →Permanent SEC source ↗
Share

Company context

We are a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.

Current securities

INTSNASDAQ · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial ConditionAug 11, 2026
  2. 10-Q filingAug 11, 2026
  3. 4 filingJul 20, 2026
  4. 4 filingJul 20, 2026
  5. 4 filingJul 20, 2026

As-filed source

Primary evidence
As filedOpen full document ↗